A -- LAWRENCE LIVERMORE NATIONAL LABORATORY SEEKS PARTNER(S) TO EVALUATE AND COMMERCIALIZE ITS CANCER TREATMENT COMPUTATIONAL MODEL

Notice Date

February 21, 2001

Contracting Office

Lawrence Livermore National Laboratory, 7000 East Avenue, Livermore, CA 94550

ZIP Code

94550

Solicitation Number

CBD01-004

Response Due

April 23, 2001

Point of Contact

Industrial Partnerships and Commercialization office (925) 423-3139

Description

Lawrence Livermore National Laboratory (LLNL), operated by the University of California under contract with the U.S. Department of Energy (DOE), is seeking one or more industrial partners to evaluate and commercialize its computational model that predicts and determines optimal treatments for individual cancer patients. The predictions and determination of optimal treatments are based on individual patient's particular tumor cell kinetics and drug resistances. By inputting drug resistance data and cell kinetics data such as apoptotic index, proliferative index, S-phase fraction, and cell cycle time, the mathematical model can successfully predict optimal drug combinations, doses, and schedule to reduce tumor size and prolong patient life. Model predictions are supported by clinical findings. For example, clinical findings supported model predictions that including cytostatic drugs during treatment with cytotoxic drugs would dramatically increase the probability of cure and prolong patient life and that schedule modifications might be more effective than dose escalation. In addition, the model predicted cancer treatment regimens for breast cancer patients and the predicted regimens matched with the most effective treatment regimens in clinical trials. The invention can be used to assist doctors to determine optimal treatments for individual cancer patients. With modification, the model can also be used to determine the optimal treatments for viral and bacterial diseases. LLNL is looking for industrial partners to add a user-friendly interface, carry out further stringent clinical tests on the model, and finally commercialize the invention. Note: THIS IS NOT A PROCUREMENT. Companies interested in commercializing LLNL's cancer treatment computational model should provide a written statement of interest including a commercialization plan and a description of corporate capabilities relevant to commercializing the technology. Written responses should be directed to: Lawrence Livermore National Laboratory Industrial Partnerships and Commercialization P. O. Box 808, L-795 Livermore, CA 94551-0808 Attention: CBD01-004 Please provide your written statement by April 23, 2001, to ensure consideration of your interest in LLNL's cancer treatment computational model.

Record

Loren Data Corp. 20010223/ASOL007.HTM (W-052 SN50E251)